Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI™ (berdazimer) Topical Gel, 10.3%
Pelthos Therapeutics Inc. (PTHS)
Company Research
Source: GlobeNewswire
ZELSUVMI is the first and only FDA-approved at-home treatment for molluscum contagiosum, a highly contagious viral skin condition affecting an estimated 16.7 million people, with up to 6 million new incidents reported every year in the United States DURHAM, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it has signed its first commercial agreement to expand patient access for ZELSUVMI™ (berdazimer) topical gel, 10.3%, for the treatment of molluscum contagiosum in adults and pediatric patients one year of age and older (“ZELSUVMI”). Pelthos has entered into an agreement with a Group Purchasing Organization that collaborates with manufacturers on behalf of one of the largest Pharmacy Benefit Managers (“PBMs”) in the United States. The PBM manages prescription drug benefits for more than 20 million cove
Show less
Read more
Impact Snapshot
Event Time:
PTHS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PTHS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PTHS alerts
High impacting Pelthos Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
PTHS
News
- Pelthos Therapeutics to Present at the Piper Sandler 37th Annual Healthcare ConferenceGlobeNewswire
- Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
- Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial ResultsGlobeNewswire
- Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes FinancingGlobeNewswire
- Pelthos Therapeutics to Report Third Quarter 2025 Financial Results on November 13, 2025GlobeNewswire
PTHS
Earnings
- 11/13/25 - Miss
PTHS
Sec Filings
- 12/1/25 - Form ARS
- 11/26/25 - Form 4
- 11/25/25 - Form DEF
- PTHS's page on the SEC website